AstraZeneca's Heart Drug Misfire: What It Means for Clinical Trials and Big Pharma The pharmaceutical industry has long faced criticism for prioritizing profit over patient outcomes.
Recent developments surrounding AstraZeneca's Wainua heart disease treatment serve as a stark reminder of this issue.
The British drugmaker's shares plummeted 9% after a late stage clinical trial failed to meet its target, raising doubts about the efficacy of this particular medication.